Genetic Testing in the Clinic for the APOE gene: A Cautionary Tale

Add to your list(s) Download to your calendar using vCal

• Dr Margaret Lock. See: www.mcgill.ca/ssom/facultyinfo/lock/
• Wednesday 25 November 2009, 13:00-14:00
• Institute of Public Health, University Forvie Site, Addenbrooke's site, small seminar room.

If you have a question about this talk, please contact Hannah Keage: hk323.

It is commonly assumed that costs of individual genotyping will steadily decrease over the next few years, leading certain researchers and policy makers to argue that genetic testing for certain complex diseases should be routinized to improve clinical care. In this presentation I will first indicate some of the difficulties involved in conveying the complex, unfolding knowledge about AD genetics to patients, their families, and the public at large. Findings will then be presented from interviews with individuals, themselves unaffected by AD, but whose families have one or more member diagnosed with AD, and who participated in the Risk Evaluation and Education for Alzheimer’s Disease study, an RCT carried out at four sites in the US in which subjects were genotyped and informed about their APOE status. One year later, less than one quarter of the interviewees recall their genotype or risk estimates correctly and family history is regarded by virtually all as a better indicator of future disease than is genetic testing. The questionable worth of individualized risk estimates will also be discussed.

This talk is part of the Cambridge Neuroscience Seminars series.

This talk is included in these lists:

• Biology
• Cambridge Neuroscience Seminars
• Cambridge talks
• Chris Davis' list
• Featured lists
• Institute of Public Health, University Forvie Site, Addenbrooke's site, small seminar room
• Life Science
• Life Sciences
• Neuroscience
• Neuroscience Seminars
• Neuroscience Seminars
• Stem Cells & Regenerative Medicine
• dh539

Note that ex-directory lists are not shown.